Clinical Trial Update: A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating gemtuzumab ozogamicin in combination with zosuquidar for CD33-positive acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)
• Zosuquidar (zosuquidar)

Snippet

Sponsor: Kanisa Pharmaceuticals | Conditions: Leukemia, Myeloid | Phase 1, Phase 2 | Status: COMPLETED